Showing results (941-950 of 991) with videos related to

Sort By:
Pageof 100
Bulletin De La Societe De Pathologie Exotique (1990)|August 23, 2015
[Clinical and immunological profile of HIV-infected patients at the initiation of antiretroviral therapy in Douala]N E Essomba, B H Mbatchou Ngahane, M Nida, et al.
Neuron|March 3, 2021
SARM1 is a metabolic sensor activated by an increased NMN/NAD<sup>+</sup> ratio to trigger axon degenerationMatthew D Figley, Weixi Gu, Jeffrey D Nanson, et al.
Cancer Immunology Research|January 24, 2025
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial CancerMatthew D Galsky, Mark Kockx, Juliette Roels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Plos Pathogens|June 14, 2022
Ucl fimbriae regulation and glycan receptor specificity contribute to gut colonisation by extra-intestinal pathogenic Escherichia coliSteven J Hancock, Alvin W Lo, Thomas Ve, et al.
Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Pageof 100